Deanna S Cross1, Mark Ritter, Douglas J Reding. 1. Center for Human Genetics; Marshfield Clinic Research Foundation, 1000 North Oak Avenue; Marshfield, WI 54449, USA. cross.deanna@mcrf.mfldclin.edu
Abstract
OBJECTIVE: To quantify outcomes of individuals diagnosed and treated for prostate cancer in a single institution. DESIGN: Retrospective electronic chart abstraction. SETTING: Marshfield Clinic, the largest private multispecialty group practice in Wisconsin, and one of the largest in the United States, provides health care services annually to approximately 385,000 unique patients through 1.8 million annual patient encounters. PARTICIPANTS: Individuals within the Marshfield Clinic cancer registry who had been diagnosed with prostate cancer between 1960 and 2009. METHODS: Electronic chart abstraction from the cancer registry and the electronic medical record was conducted (N=6,181). Data abstracted included age at diagnosis; stage and grade of tumor; prostate specific antigen (PSA) values before, at, and after diagnosis; initial cancer treatment; follow-up time; subsequent cancer treatments; evidence of metastasis; age of death; and cause of death, if known. RESULTS: The average age of prostate cancer diagnosis has decreased from 70-71 years in the 1960's and 1970's to an average age at diagnosis of 67 years in the 2000's (P<0.001). This decrease in age occurred within the decades of implementation of PSA screening. Approximately 74% of men diagnosed with prostate cancer within the PSA screening era had at least one PSA test, and the presence of a PSA test did not appear to change treatment outcome. Age, grade, and stage were the biggest predictors of prostate cancer outcome. There was no difference in event-free survival between current treatment types (radical prostatectomy, brachytherapy, photon treatment, or intensity-modulated radiation therapy) (2003 or later) when stratified by age (greater than 85%, 5-year event-free survival P=0.85); however, more events occurred with older external beam radiation treatment regimens (1993-2003) (70% to 75%, 5-year event-free survival P=0.001). CONCLUSION: Individuals diagnosed and treated for prostate cancer within the Marshfield Clinic comprehensive care setting follow national trends with a decreased age of diagnosis since the advent of PSA screening. Outcomes for individuals treated within the Clinic system are also comparable to national trends.
OBJECTIVE: To quantify outcomes of individuals diagnosed and treated for prostate cancer in a single institution. DESIGN: Retrospective electronic chart abstraction. SETTING: Marshfield Clinic, the largest private multispecialty group practice in Wisconsin, and one of the largest in the United States, provides health care services annually to approximately 385,000 unique patients through 1.8 million annual patient encounters. PARTICIPANTS: Individuals within the Marshfield Clinic cancer registry who had been diagnosed with prostate cancer between 1960 and 2009. METHODS: Electronic chart abstraction from the cancer registry and the electronic medical record was conducted (N=6,181). Data abstracted included age at diagnosis; stage and grade of tumor; prostate specific antigen (PSA) values before, at, and after diagnosis; initial cancer treatment; follow-up time; subsequent cancer treatments; evidence of metastasis; age of death; and cause of death, if known. RESULTS: The average age of prostate cancer diagnosis has decreased from 70-71 years in the 1960's and 1970's to an average age at diagnosis of 67 years in the 2000's (P<0.001). This decrease in age occurred within the decades of implementation of PSA screening. Approximately 74% of men diagnosed with prostate cancer within the PSA screening era had at least one PSA test, and the presence of a PSA test did not appear to change treatment outcome. Age, grade, and stage were the biggest predictors of prostate cancer outcome. There was no difference in event-free survival between current treatment types (radical prostatectomy, brachytherapy, photon treatment, or intensity-modulated radiation therapy) (2003 or later) when stratified by age (greater than 85%, 5-year event-free survival P=0.85); however, more events occurred with older external beam radiation treatment regimens (1993-2003) (70% to 75%, 5-year event-free survival P=0.001). CONCLUSION: Individuals diagnosed and treated for prostate cancer within the Marshfield Clinic comprehensive care setting follow national trends with a decreased age of diagnosis since the advent of PSA screening. Outcomes for individuals treated within the Clinic system are also comparable to national trends.
Authors: Renske Postma; Fritz H Schröder; Geert J L H van Leenders; Robert F Hoedemaeker; Andre N Vis; Monique J Roobol; Theodorus H van der Kwast Journal: Eur Urol Date: 2007-01-16 Impact factor: 20.096
Authors: John W Colberg; Roy H Decker; Anwar M Khan; Ann McKeon; Lynn D Wilson; Richard E Peschel Journal: Cancer J Date: 2007 Jul-Aug Impact factor: 3.360
Authors: Jim C Hu; Nathanael D Hevelone; Marcos D Ferreira; Stuart R Lipsitz; Toni K Choueiri; Martin G Sanda; Craig C Earle Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: Patrick A Kupelian; Jay Ciezki; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-08 Impact factor: 7.038
Authors: Alexandre E Pelzer; Daniela Colleselli; Jasmin Bektic; Georg Schaefer; Stefano Ongarello; Christian Schwentner; Leo Pallwein; Michael Mitterberger; Eberhard Steiner; Georg Bartsch; Wolfgang Horninger Journal: BJU Int Date: 2008-03-13 Impact factor: 5.588